

# Eric J Small

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8708809/publications.pdf>

Version: 2024-02-01

86  
papers

18,082  
citations

109264

35  
h-index

71651

76  
g-index

87  
all docs

87  
docs citations

87  
times ranked

16652  
citing authors

| #  | ARTICLE                                                                                                                                                                                                                                                                                       | IF  | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1  | OUP accepted manuscript. <i>Oncologist</i> , 2022, , .                                                                                                                                                                                                                                        | 1.9 | 4         |
| 2  | Implementation of a Multisite Financial Reimbursement Program in Cancer Clinical Trials Integrated With Patient Navigation: A Pilot Randomized Clinical Trial. <i>JCO Oncology Practice</i> , 2022, 18, e915-e924.                                                                            | 1.4 | 7         |
| 3  | Predictive Biomarkers of Overall Survival in Patients with Metastatic Renal Cell Carcinoma Treated with IFN $\gamma$ + Bevacizumab: Results from CALGB 90206 (Alliance). <i>Clinical Cancer Research</i> , 2022, 28, 2771-2778.                                                               | 3.2 | 8         |
| 4  | Mobile Clinical Trial Matching Technology in Medical Oncology Clinic: A Pilot Feasibility Study. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100182.                                                                                                                                  | 1.0 | 0         |
| 5  | CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease. <i>Clinical Cancer Research</i> , 2022, 28, 3066-3075.                                                                                      | 3.2 | 10        |
| 6  | Examining reporting and representation of patients with cancer in COVID-19 clinical trials. <i>Cancer Reports</i> , 2021, 4, e1355.                                                                                                                                                           | 0.6 | 2         |
| 7  | Differential treatment outcomes in <i>BRCA1/2</i> , <i>CDK12</i> , and <i>ATM</i> mutated metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2021, 127, 1965-1973.                                                                                                              | 2.0 | 15        |
| 8  | Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. <i>Cancer</i> , 2021, 127, 2623-2630. | 2.0 | 2         |
| 9  | Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. , 2021, 9, e002254.                                                                                                       |     | 21        |
| 10 | An integrated functional and clinical genomics approach reveals genes driving aggressive metastatic prostate cancer. <i>Nature Communications</i> , 2021, 12, 4601.                                                                                                                           | 5.8 | 18        |
| 11 | Baseline Testosterone Levels in Men with Clinically Localized High-Risk Prostate Cancer Treated with Radical Prostatectomy with or without Neoadjuvant Chemohormonal Therapy (Alliance). <i>Journal of Urology</i> , 2021, 206, 319-324.                                                      | 0.2 | 1         |
| 12 | Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 1644.                                                                                                                                                                     | 3.4 | 21        |
| 13 | A multidisciplinary team-based approach with lifestyle modification and symptom management to address the impact of androgen deprivation therapy in prostate cancer: A randomized phase II study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 730.e9-730.e15.  | 0.8 | 2         |
| 14 | Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis. <i>Journal of Cancer Policy</i> , 2021, 30, 100305.                                                                         | 0.6 | 13        |
| 15 | The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. <i>Nature Communications</i> , 2021, 12, 7349.                                                                                                                                                       | 5.8 | 51        |
| 16 | Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2021, , OP2100480.                                                                                                                                          | 1.4 | 1         |
| 17 | Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. <i>European Urology</i> , 2020, 77, 333-341.                                                                                                                                                                 | 0.9 | 65        |
| 18 | Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e180-e189.                                                                                           | 0.9 | 15        |

| #  | ARTICLE                                                                                                                                                                                                                                                            | IF  | CITATIONS |
|----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Hyperpolarized <sup>13</sup> C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 269-276.                                     | 2.0 | 68        |
| 20 | The DNA methylation landscape of advanced prostate cancer. <i>Nature Genetics</i> , 2020, 52, 778-789.                                                                                                                                                             | 9.4 | 198       |
| 21 | Accelerating precision medicine in metastatic prostate cancer. <i>Nature Cancer</i> , 2020, 1, 1041-1053.                                                                                                                                                          | 5.7 | 45        |
| 22 | Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3042-3050.                                          | 0.8 | 60        |
| 23 | Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa003.                                                                                                | 1.4 | 1         |
| 24 | Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 931.e9-931.e16. | 0.8 | 4         |
| 25 | Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?. <i>Contemporary Clinical Trials</i> , 2020, 92, 105997.                                                                                       | 0.8 | 8         |
| 26 | Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. <i>Future Oncology</i> , 2019, 15, 2337-2348.                                                                        | 1.1 | 15        |
| 27 | The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. <i>Clinical Cancer Research</i> , 2019, 25, 6916-6924.                                                                                                                                       | 3.2 | 200       |
| 28 | A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. <i>Pilot and Feasibility Studies</i> , 2019, 5, 123.                 | 0.5 | 7         |
| 29 | Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. <i>Molecular Cancer Research</i> , 2019, 17, 1235-1240.                                                           | 1.5 | 51        |
| 30 | Reply to A. Dalla Volta et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 351-352.                                                                                                                                                                            | 0.8 | 0         |
| 31 | Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 562-571.                                                                                                     | 0.9 | 104       |
| 32 | MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 531-538.                                                                                                   | 2.0 | 66        |
| 33 | Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-410.                                                                                      | 0.8 | 83        |
| 34 | How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. <i>Contemporary Clinical Trials Communications</i> , 2019, 16, 100476.                             | 0.5 | 10        |
| 35 | Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019, 25, 2450-2457.                                                                                                                          | 3.2 | 52        |
| 36 | Apalutamide and its use in the treatment of prostate cancer. <i>Future Oncology</i> , 2019, 15, 591-599.                                                                                                                                                           | 1.1 | 5         |

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                             | IF   | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 37 | Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2019, 60, 910-916.                                                                                                                           | 2.8  | 35        |
| 38 | Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.                                                                                                                                                             | 2.3  | 943       |
| 39 | Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. <i>Cancer</i> , 2018, 124, 1383-1390.                                                                                                              | 2.0  | 6         |
| 40 | Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 184-190.e2.                                                                                                               | 0.9  | 13        |
| 41 | Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 2492-2503.                                                                                                                          | 0.8  | 477       |
| 42 | Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. <i>Therapeutic Advances in Urology</i> , 2018, 10, 445-454.                                                                                                                                                                      | 0.9  | 10        |
| 43 | Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. <i>Cell</i> , 2018, 174, 758-769.e9.                                                                                                                                                                                                                      | 13.5 | 459       |
| 44 | A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 149.e7-149.e13. | 0.8  | 7         |
| 45 | Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of <i>BRCA2</i> Reversion Mutations Associated with Resistance to PARP Inhibitors. <i>Cancer Discovery</i> , 2017, 7, 999-1005.                                                                                                                          | 7.7  | 223       |
| 46 | Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1221-1229.                                                                                                                                                                                                       | 1.5  | 27        |
| 47 | Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 625-633.                                                                                                                                                                  | 1.1  | 24        |
| 48 | CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1073-1081.e1.                                                                                                                            | 0.2  | 30        |
| 49 | Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .                                                                                                                                                                        | 3.0  | 288       |
| 50 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 591-597.                                                                                              | 0.8  | 584       |
| 51 | Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. <i>Oncotarget</i> , 2017, 8, 71447-71455.                                                                                                             | 0.8  | 23        |
| 52 | Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. <i>European Urology Focus</i> , 2016, 2, 469-471.                                                                                        | 1.6  | 12        |
| 53 | A Feasibility Study Showing [ <sup>68</sup> Ga]Citrate PET Detects Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2016, 18, 946-951.                                                                                                                                                                                       | 1.3  | 33        |
| 54 | Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. <i>Clinical Cancer Research</i> , 2016, 22, 4890-4900.                                                                                                           | 3.2  | 46        |

| #  | ARTICLE                                                                                                                                                                                                                                                                                                                                                                   | IF   | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 55 | An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. <i>Cancer Letters</i> , 2016, 380, 144-152.                                                                                                                                                                     | 3.2  | 26        |
| 56 | Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. <i>Journal of Clinical Oncology</i> , 2016, 34, 1402-1418.                                                                                                                                                        | 0.8  | 1,089     |
| 57 | Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.                                                                                                                                                                                | 0.8  | 332       |
| 58 | Prospects for the use of ipilimumab in treating advanced prostate cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 421-432.                                                                                                                                                                                                                                | 1.4  | 5         |
| 59 | Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. <i>Cancer Immunology Research</i> , 2015, 3, 1008-1016.                                                                                                                                                                            | 1.6  | 49        |
| 60 | Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e191-e198. | 0.9  | 9         |
| 61 | Radiographic Progression-Free Survival As a Response Biomarker in Metastatic Castration-Resistant Prostate Cancer: COU-AA-302 Results. <i>Journal of Clinical Oncology</i> , 2015, 33, 1356-1363.                                                                                                                                                                         | 0.8  | 120       |
| 62 | Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 2315-2324.                                                                                                                                                                     | 3.2  | 407       |
| 63 | Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, .                                                                                                                                                                        | 3.0  | 163       |
| 64 | Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. <i>New England Journal of Medicine</i> , 2013, 368, 138-148.                                                                                                                                                                                                                                     | 13.9 | 2,412     |
| 65 | The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 1-15.                                                                                                                                                                                    | 0.3  | 2         |
| 66 | Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2010, 363, 411-422.                                                                                                                                                                                                                                         | 13.9 | 4,724     |
| 67 | Immunotherapy for Prostate Cancer. <i>American Journal of Cancer</i> , 2006, 5, 331-339.                                                                                                                                                                                                                                                                                  | 0.4  | 0         |
| 68 | The Case for Secondary Hormonal Therapies in the Chemotherapy Age. <i>Journal of Urology</i> , 2006, 176, S66-71.                                                                                                                                                                                                                                                         | 0.2  | 37        |
| 69 | Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. <i>New England Journal of Medicine</i> , 2004, 351, 1513-1520.                                                                                                                                                                                              | 13.9 | 3,344     |
| 70 | Overview of bladder cancer trials in the Cancer and Leukemia Group B. <i>Cancer</i> , 2003, 97, 2090-2098.                                                                                                                                                                                                                                                                | 2.0  | 33        |
| 71 | Hormonal treatment for prostate cancer. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 493-510.                                                                                                                                                                                                                                                               | 1.9  | 10        |
| 72 | Serum Prostate Specific Antigen as a Predictor of Survival in Prostate Cancer Patients Treated with Second-Line Hormonal Therapy (CALGB 9181). <i>Prostate Journal</i> , 2001, 3, 18-25.                                                                                                                                                                                  | 0.2  | 5         |

| #  | ARTICLE                                                                                                                                                                                                                                            | IF  | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate Cancer. American Journal of Clinical Pathology, 2001, 116, 234-239.                                                                                                | 0.4 | 70        |
| 74 | Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma. Cancer, 2000, 88, 1310-1316.                                                                                                                               | 2.0 | 19        |
| 75 | Therapy of Advanced Prostate Cancer: Part I: Antiandrogen Withdrawal, Androgen Receptor Mutations, and Secondary Hormonal Manipulations. Prostate Journal, 2000, 2, 116-122.                                                                       | 0.2 | 0         |
| 76 | Therapy of Advanced Prostate Cancer Part II: Response End Points and the Use of Chemotherapy. Prostate Journal, 2000, 2, 173-178.                                                                                                                  | 0.2 | 0         |
| 77 | Suramin Therapy for Patients With Symptomatic Hormone-Refractory Prostate Cancer: Results of a Randomized Phase III Trial Comparing Suramin Plus Hydrocortisone to Placebo Plus Hydrocortisone. Journal of Clinical Oncology, 2000, 18, 1440-1450. | 0.8 | 176       |
| 78 | Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. , 1999, 86, 2160-2165.                                                                                                                                            |     | 8         |
| 79 | The Treatment of Advanced Prostate Cancer with Ketoconazole. Drug Safety, 1999, 20, 451-458.                                                                                                                                                       | 1.4 | 28        |
| 80 | Pyrazoloacridine for the Treatment of Hormone-Refractory Prostate Cancer. Cancer Investigation, 1998, 16, 456-461.                                                                                                                                 | 0.6 | 12        |
| 81 | Ketoconazole Retains Activity in Advanced Prostate Cancer Patients with Progression Despite Flutamide Withdrawal. Journal of Urology, 1997, 157, 1204-1207.                                                                                        | 0.2 | 193       |
| 82 | Re: Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide Treatment. Journal of Urology, 1996, 155, 1704-1705.                                                                                                        | 0.2 | 0         |
| 83 | A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. , 1996, 78, 1775-1780.                                                                                                      |     | 23        |
| 84 | The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 1995, 76, 1428-1434.                                                                                              | 2.0 | 162       |
| 85 | Nephrectomy for metastatic renal cell carcinoma: A component of systemic treatment regimens. Journal of Surgical Oncology, 1994, 55, 7-13.                                                                                                         | 0.8 | 36        |
| 86 | A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer, 1994, 73, 2803-2807.                                                    | 2.0 | 2         |